Is 2.5 mg weekly a defensible maintenance dose for tirzepatide?

The case in front of me: 2.5 mg · tirzepatide.

I want to decide this in advance so that I am not deciding it under pressure later.

Assume I will follow the plan I write down, so I would like it to be a good one.

What should I decide now, and what should I defer?

Put another way, the steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

In practice, the titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

Mechanically, holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

Mechanically, what the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

Missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

One qualification — this is protocol arithmetic and reported practice, not a recommendation. The compounds in question are not approved for human use when supplied for research.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.

For a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

I would add that tolerability is not a proxy for benefit. Tolerating a higher dose easily is not evidence that you need one.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.